Novel PET tracers in the management of cardiac sarcoidosis.

Novel PET tracers in the management of cardiac sarcoidosis. Curr Radiopharm. 2020 Jun 02;: Authors: Miceli A, Raffa S, Donegani MI, Cossu V, Morbelli S, Marini C, Sambuceti G, Bauckneht M Abstract Sarcoidosis is a systemic inflammatory disease of unknown etiology, pathologically characterized by non-caseating granulomas involving several organs and tissues. This pathological process can eventually affect the heart during his course leading to fibrosis associated with systolic dysfunction, conduction disturbance, and even sudden cardiac death. Due to this prognostic impact, diagnosis is crucial to optimize clinical management. The low sensitivity of endomyocardial biopsy and its invasive nature prevents its application as a first-line diagnostic approach. Thus, several efforts have been dedicated to the identification of advanced imaging tools for the diagnosis and monitoring of cardiac involvement in systemic sarcoidosis, including Positron Emission Tomography (PET). Starting from strengths and disadvantages of 18F-Fluorodeoxyglucose (18F-FDG) PET imaging, the present narrative review will summarize state of the art and future perspectives about radiotracers other than 18F-FDG of potential interest in the field of CS, including somatostatin receptor-ligands, proliferation markers and hypoxia displaying agents. PMID: 32484775 [PubMed - as supplied by publisher]
Source: Current Radiopharmaceuticals - Category: Radiology Tags: Curr Radiopharm Source Type: research

Related Links:

AbstractCardiac sarcoidosis (CS) is an increasingly recognized condition, but cardiac magnetic resonance (CMR) image interpretation in these patients may be challenging as findings are often non-specific. The main objective of this study was to investigate the inter-reader agreement for the overall interpretation of CMR for the diagnosis of CS in an experienced reference center and investigate factors that may lead to discrepancies between readers. Consecutive patients undergoing CMR imaging to investigate for CS were included. CMR images were independently reviewed by two readers, blinded to all clinical, imaging and demo...
Source: The International Journal of Cardiovascular Imaging - Category: Radiology Source Type: research
Semin Respir Crit Care Med DOI: 10.1055/s-0040-1712535Approximately 5% of patients with sarcoidosis will have clinically manifest cardiac involvement presenting with one or more of ventricular arrhythmias, conduction abnormalities, and heart failure. It is estimated that another 20 to 25% of pulmonary/systemic sarcoidosis patients have asymptomatic cardiac involvement (clinically silent disease). Cardiac presentations can be the first (and/or an unrecognized) manifestation of sarcoidosis in a variety of circumstances. Immunosuppression therapy (usually with corticosteroids) has been suggested for the treatment of clinicall...
Source: Seminars in Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Review Article Source Type: research
ConclusionsDiagnostic yield with the new JCS guidelines was higher, with approximately 1.5 ‐fold of the patients diagnosed with CS compared with the previous international criteria and definitive iCS accounting for approximately 20% of the whole CS cohort. In addition to 75% of the patients with sCS or definitive iCS in the updated guidelines, 10% in whom CS was not documented were also started on corticosteroids for clinical indications such as reduced cardiac function or arrhythmia.
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
CONCLUSION: In the literature, calcium metabolic disorder and renal involvement have not been reported among patients with Sarcoidosis and Sjögren's syndrome, suggesting that calcium metabolic disorder may be underestimated. Serum and urine calcium concentration should be measured in addition to routine laboratory test. PMID: 32560621 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Authors: Ostwani W, Hanna C, Brice AE, Wymer DC Abstract A case of a patient with suspected of myocardial ischemia, with multiple normal perfusion scans, is diagnosed with isolated cardiac sarcoidosis on fluorine-18 (18F)-fluorodeoxyglucose (FDG)-positron emission tomography (PET). The diagnosis and monitoring disease response using imaging follow-up are discussed in this report. PMID: 32518122 [PubMed - as supplied by publisher]
Source: Journal of Nuclear Medicine Technology - Category: Nuclear Medicine Tags: J Nucl Med Technol Source Type: research
While most sarcoidosis patients have a favourable outcome, up to one third have significant morbidity with an overall disease related mortality about five percent1;2. The rate of hospitalization and death from sarcoidosis has risen over the past 30 years2;3. Since a third of sarcoidosis patients have clinically significant major organ involvement, Wells suggested that sarcoid-associated mortality is 20-25% in these patients4. In Europe and the USA, death from sarcoidosis is usually the result of respiratory failure associated with fibrotic lung disease1;2;5.
Source: Respiratory Medicine - Category: Respiratory Medicine Authors: Source Type: research
Conclusions: According to this study, ventilatory limitation, pulmonary involvement, and deconditioning are the main causes of activity limitations in sarcoidosis patients. PMID: 32476953 [PubMed - in process]
Source: Sarcoidosis Vasculitis and Diffuse Lung Diseases - Category: Respiratory Medicine Tags: Sarcoidosis Vasc Diffuse Lung Dis Source Type: research
AbstractPurpose of ReviewGoal of this review article was to summarize and evaluate the current developments in nuclear medicine cardiovascular imaging with focus on PET/MR imaging. Furthermore, it should highlight recent topics of interest, such as sarcoidosis, inflammation, and cardiac amyloidosis for instance, which have not properly characterized with PET/MRI yet.Recent FindingsIn the last years there have been advances in experimental tracers and clinical research especially for inflammatory cardiac diseases. Most articles still focus PET/CT rather than PET/MRI, which is mostly due to a limited number of PET/MRI center...
Source: Current Cardiovascular Imaging Reports - Category: Radiology Source Type: research
Abstract Cardiovascular diseases are the most common cause of death in patients over 60 years old. Imaging methods of a pivotal role in cardiological diagnostic processes are echocardiography, magnetic resonance, multi-row-detector computed tomography, coronary angiography, and radioisotope tests. In this paper, we summarize the techniques of nuclear medicine (positron emission tomography, single-photon emission computed tomography, radionuclide ventriculography) that could be implemented in the cardiovascular diagnostic algorithms. Despite being acknowledged and positioned in a few cardiological guidelines, these...
Source: Polish Heart Journal - Category: Cardiology Authors: Tags: Kardiol Pol Source Type: research
AbstractBackgroundQuantitative assessment of cardiac hypermetabolism from18Flourodeoxy glucose (FDG) positron emission tomography (PET) may improve diagnosis of cardiac sarcoidosis (CS). We assessed different approaches for quantification of cardiac hypermetabolism and perfusion in patients with suspected CS.Methods and resultsConsecutive patients undergoing18FDG PET assessment for possible CS between January 2014 and March 2019 were included. Cardiac hypermetabolism was quantified using maximal standardized uptake value (SUVMAX), cardiometabolic activity (CMA) and volume of inflammation, using relative thresholds (1.3 &ti...
Source: Journal of Nuclear Cardiology - Category: Nuclear Medicine Source Type: research
More News: Cardiology | Heart | PET Scan | Radiology | Sarcoidosis